Previous 10 | Next 10 |
--News Direct-- This #GivingTuesday we recognize the many employees who take time to support members of our communities who are in need. More than 10 years ago, we launched Alkermes in Action, an annual employee volunteer program designed to support volunteer efforts within our local co...
--News Direct-- While one overdose is one too many, we now mourn the loss of the 100,000+ Americans lost to this epidemic in just one year. We reaffirm our commitment to drive awareness and action to make change for people affected by addiction: https://bit.ly/3qTL4Yi Vie...
Alkermes to Take Part in the Fourth Annual Evercore ISI HealthCONx Conference PR Newswire DUBLIN , Nov. 24, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the fourth annual Evercore ...
--News Direct-- November is National Family Caregivers Month and as we prepare for Thanksgiving, it is a perfect opportunity to express our sincerest gratitude to family caregivers. Caregivers are invaluable throughout a patient’s cancer journey, tirelessly providing support...
Alkermes Announces the Appointment of Cato T. Laurencin, M.D., Ph.D. to its Board of Directors PR Newswire DUBLIN , Nov. 19, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the appointment of a new independent director, Cato T. Laurencin, M.D...
Alkermes (NASDAQ:ALKS) announces dosing of the first subject in a phase 1 study evaluating the safety and tolerability of ALKS 1140 in healthy adults. ALKS 1140 is a novel, investigational CoREST-selective HDAC (histone deacetylase) inhibitor candidate for the treatment of neurodegenerat...
Alkermes Announces First Subject Dosed in Phase 1 Study of ALKS 1140 for the Treatment of Neurodegenerative and Neurological Disorders PR Newswire DUBLIN , Nov. 11, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced dosing of the first subje...
Alkermes to Take Part in the Stifel Virtual Healthcare Conference PR Newswire DUBLIN , Nov. 9, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Stifel Virtual Healthcare Confe...
Shares of Alkermes (NASDAQ: ALKS) were sinking 14.3% as of 11 a.m. EST on Tuesday. The decline came after the company announced on Monday that it had received notices of partial termination from Johnson & Johnson 's (NYSE: JNJ) Janssen subsidiary related to license agree...
Alkermes (NASDAQ:ALKS) has lost ~12.0% in the post-market after announcing that Janssen Pharmaceutical of Johnson & Johnson (NYSE:JNJ) has notified the company regarding termination of licensing agreements for its NanoCrystal technology. The termination that will become eff...
News, Short Squeeze, Breakout and More Instantly...
Alkermes to Report Second Quarter Financial Results on July 24, 2024 PR Newswire DUBLIN , July 17, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. BST ) on Wednesday, ...
2024-06-29 16:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-19 17:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...